Joaquin Duato Chief Executive Officer Johnson & Johnson “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers. Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on January 25, 2022, available at http://www.investor.jnj.com/sales-earnings.cfm. *Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Non-GAAP measure; excludes the impact of translational currency. Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward- Looking Statements” included in the Johnson & Johnson earnings release issued on January 25, 2022, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Full Year 2021 Results 2021 Sales Adjusted Diluted Earnings Per Share* $9.80 22.0% Increased  Diluted Earnings Per Share $7.81 41.7% Increased  Worldwide Increased  $93.8B 12.8%* 13.6% Worldwide Increased  Excluding acquisitions/ divestitures on an operational basis Note: values may have been rounded $27.1Medical Devices worldwide reported sales increased 17.9% or 16.2% operationally¹. Primary operational drivers: Worldwide Medical Devices Sales Billion Surgical Vision Wound Closure Electrophysiology Contact Lens Trauma Endocutters Energy Biosurgery Hips Knees Billion $52.1 Worldwide Pharmaceutical SalesPharmaceutical worldwide reported sales increased 14.3% or 13.1% operationally¹. Primary operational drivers: Consumer Health worldwide reported sales increased 4.1% or 2.8% operationally¹. Primary operational drivers: $14.6 Worldwide Consumer Health Sales Billion -- 1 of 1 --